Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PHAR 505 > Quantification of drug-target interactions > Flashcards

Quantification of drug-target interactions Flashcards

1
Q

Define the Molecular mechanisms of action

A

The interactions between a drug and a target that leads to a specific outcome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What parameters must be considered When measureing MMOA?

A 
The kinetics (Reversible versus irreversible binding)
The Binding Site (Orthosteric vs allosteric)
The functional effect (activation vs inhibition)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

During reversible equilibrium binding of a drug to its target ligand or receptor, Kd and Ki are ____, Inhibition can be ___ or ____, and potential competition can come from ____, ____, or ____

A

equal

orthosteric
allosteric

Enzyme
Protein:protein interaction inhibitor
Receptor antagonist

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Define competitive inhibition

A

Neither the ligand nor the drug can bind at the same time

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Define uncompetitive inhibition

A

The inhibitor binds the enzyme/receptor only when the natural ligand is bound (potency is proportional to the physiological concentration of the ligand)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Define noncompetitive inhibition

A

The inhibitor reduces the activity of the enzyme/receptor and binds to an allosteric site, whether it has the ligand bound or not

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Define agonism

A

Binding of compound activates the receptor or enzyme (can be full or partial)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Define allosteric modulation

A

Binding of compound will modify the activity of a receptor or enzyme, thereby shifting its substrate selectivity profile

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

How do you calculate the Kd for receptor:binding at equilibrium? What is the unit?

A

k_off/k_on
Molar
The lower the number, the stronger the interaction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is receptor occupancy and how is it calculated during Receptor:ligand binding at equilibrium?

A

The fraction of receptors bound over all receptors

Y = [R:L]/[Rtotal]
Where [Rtotal] = [Rfree] + [R:L]

or

If the receptor concentration is much lower than the ligand concentration of Kd (often the case):
Y = [Ltotal]/([Ltotal] + Kd)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What property is seen when plotting Receptor occupancy over ligand concentration semilogarithmically?

A

All concentrations show the same curve, just shifted left/right

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Define cooperativity

A

When the binding of a ligand influences binding at another site (oligomeric receptors display this behaviour often)

Can be positive or negative cooperativity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

How is cooperativity modelled mathematically?

A

Y = [L]/([L] +Kd)

Raise the two [L]s and Kd by the Hill coefficient n

A Hill coefficient above 1 shows positive cooperativity

”” below 1 shows negative cooperativity (rare)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How do you calculate Receptor occupancy during reversible competitive inhibition?

A 
Y = [RL]/[Rtotal]
or
Y = [L]/([L]+K_L(1 + [I]/K-I))
or
[L]/([L] + K_app)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How do you calcualte receptor occupancy during irreversible competitive inhibition?

A 
Y = [RL]/[Rtotal]
or
Y = [L]/([L] + K_L)
or
[R_unmodified]/[R_total]
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

When is K_app = [L]?

A

When Y = 0.5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is the K_internal of a two-state model of receptor activation? what is the equation?

A

The rate at which a receptor switches from an inactive form to its active form

K_int = [R^A]/[R^I]

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

How d you calculate apparent K_d in a two-state model for an agonist?

A

K_appD = Kd(1+ 1/Kint)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

How d you calculate apparent K_d in a two-state model for an inverse agonist?

A

K_appD = Kd(1+K_int)

20
Q

What is a partial agonist and how do you calculate its apparent K_d?

A

An agonist that binds to both active an inactive forms of a two-state receptor (can be positive or negative depending of affinity)

K_appD = (Kint +1)/((K_int/K_A) + (1/K_I))

Where
K_A = [R^A][A]/[R^A:A]
K_I = [R^A][A]/[R^I:A]

21
Q

At saturating concentrations, a full agonist will lead to _____ whereas an inverse agonist will lead to _____

A partial agonist will lead to ____, and a neutral antagonist leads to ______

A

Full receptor activation
Full inactivation

Partial activation or inactivation

Competitive inhibition (antagonizes the action of another agonist)

22
Q

Why does Y not start at 0 in dose response curves?

A

Even without ligand there’s always an equilibrium between active/inactive forms

23
Q

Where is K_app on a dose-response graph?

A

Halfway between minimal response and maximal response (the inflection point of the curve)

24
Q

What is the enzymatic k_cat

A

The rate at which an enzyme catalyzes a substrate into its product

25
Q

How do you use the Michaelis-Menten equation and what is it?

A

It relates the initial rate of product formation (v0) to the substrate concentration

v0 = k_cat[E:S] = d[P]/dt (slope of velocity/conc)

26
Q

When do you use the Briggs-Haldane approximation?

A

When the enzyme concentration is much smaller than substrate concentration

27
Q

What is K_M?

A

The substrate concentration at which the rate is equal to V_max/2 (most efficient)

28
Q

How do competitive, noncompetitive and uncompetitive inhibition affect K_M, if at all?

A

Competitive: shifts rightwards as [I] increase

Noncompetitive: K_M stays the same but V_max lowers as [I] rises

Uncompetitive: same as noncompetitive

29
Q

Why don’t humans develop noncompetitive inhibitors instead of competitive inhibitors (noncompetitive works better)?

A

Because we don’t always know the allosteric binding site, often discovered by chance

30
Q

What is residence time?

A

The time the ligand spends in complex with the receptor

1/k_off

31
Q

What is residence time proportional to?

A

Half life

32
Q

Why shouldn’t you use K_I to infer potency?

A

K implies equilibrium, which is hardly the case in the human body

33
Q

What is one way to increase residence time?

A

“locking” the receptor:drug complex in another state

eg E + I <=> EI <=> EI*

34
Q

What is the ED50, the TD50, and what is their relation to the therapeutic index?

A

ED is efective dose for 50% of population
TD is toxic dose for 50% of population

TI = TD/ED

35
Q

Why wouldn’t the relationship between receptor occupancy and effect be linear?

A

Eg an amplifying cascade

36
Q

How do you calculate an isobologram?

A

Measure the eg ED50 for two separate drugs

draw a dashed line from each ED50 on a graph of dose of B over dose of A (dashed line represents nointeraction, additive effect

Fix one dose and vary dose of other until same level of effect is reached (typically below dashed line)

37
Q

What is the combination index and how is it calculated?

A

How much of a synergy is present between two drugs

Conc of drug A in combination with drug B required for effect normally seen at conc X / conc X + “” drug B “” drug A

38
Q

How can Ponatinib, a drug that typically has no effect on cancer cells, be used to treat cancer cells?

A

In combination with trametinib (effective at high/toxic doses), lowers effective dose 5-fold

39
Q

What are the two mechanisms to measure interactions between molecules learned in class?

A

Surface Plasmon Resonance

Fluorescence polarization

40
Q

How does SRP work?

A

Polarized light is shone through a prism onto a gold film with surface coated by receptors (“ligands”) and a flow of liquid above it with ligands (“analytes”)

At a certain angle, light will be absorbed by the molecule

This shows as a decrease in intensity of the reflected light

You can measure this light and find out exactly at which angle the light was absorbed

The change in angle is exactly proportional to the bound mass

41
Q

How can you determine k_on from SPR?

A

At the dissociation phase you can measure k_off because there can only be dissociation

During association phase, function of both k_on and k_off (can use known k_off to find k_on)

42
Q

Why do SRP at varying concentration of “ligand”?

A

To find the (constant) K_D

43
Q

What is R_Max?

A

The highest response you can get at the highest analyte concentration

44
Q

When is the binding isotherm equation useful in SRP?

A

When the dissociation rates are faster than the SPR sampling rate

45
Q

How can you calculate the stoichiometry of a drug:receptor interaction using SRP?

A

Rmax
Ri
Stoichiometric ratio

You’ll always have two and need to find the other

Rmax is the ratio of MWs of the analyte over the ligand multiplied by the initial rate and stoichiometric ratio

46
Q

How does fluorescence anisotropy work?

A

Polarized light is shone on a molecule, and depending on the size it will move and depolarize the light of not move (if it’s bigger) and keep polarization

47
Q

What property of a fluorescent label needs to be considered and why?

A

Lifetime

Lifetime determines the shift in polarization based on change in molecular weight (smaller lifetimes for smaller changes in MW)

PHAR 505 (11 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions